Search

Your search keyword '"Montillo, Marco"' showing total 36 results
Start Over Author "Montillo, Marco" Publication Year Range Last 3 years
36 results on '"Montillo, Marco"'

1. S201: FINAL 7‐YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX‐RITUXIMAB (VENR)‐TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)

Author

Kater, Arnon, Harrup, Rosemary, Kipps, Thomas J, Eichhorst, Barbara, Owen, Carolyn J, Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Thadani‐Mulero, Maria, Lefebure, Marcus, Jiang, Yanwen, Millen, Rosemary, Boyer, Michelle, and Seymour, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Lymphatic Research, Cancer, Lymphoma, Rare Diseases, Hematology
Published
2023

2. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Author

Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, and Montillo, Marco

Published
2024
Full Text
View/download PDF

3. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Kater, Arnon P, Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H, van der Kevie-Kersemaekers, Anne-Marie F, Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J, Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E, Vizkelety, Tamas, and Forconi, Francesco

Published
2024
Full Text
View/download PDF

4. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Author

Kaufman, Matthew, Yan, Xiao-Jie, Li, Wentian, Ghia, Emanuela M, Langerak, Anton W, Rassenti, Laura Z, Belessi, Chrysoula, Kay, Neil E, Davi, Frederic, Byrd, John C, Pospisilova, Sarka, Brown, Jennifer R, Catherwood, Mark, Davis, Zadie, Oscier, David, Montillo, Marco, Trentin, Livio, Rosenquist, Richard, Ghia, Paolo, Barrientos, Jacqueline C, Kolitz, Jonathan E, Allen, Steven L, R., Kanti, Stamatopoulos, Kostas, Kipps, Thomas J, Neuberg, Donna, and Chiorazzi, Nicholas

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Lymphoma, Cancer, Hematology, Lymphatic Research, Rare Diseases, CLL, chronic lymphocytic leukemia, immunoglobulin variable domain, prognosis, somatic mutations, Oncology and Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells, B-cell receptor (BCR) signaling is likely at the heart of the worse outcomes of CLL cases without/few IGHV mutations. A corollary of this conclusion is that M-CLL follow less aggressive clinical courses because somatic IGHV mutations have altered BCR structures and no longer bind stimulatory (auto)antigens and so cannot deliver trophic signals to leukemic B cells. However, the latter assumption has not been confirmed in a large patient cohort. We tried to address the latter by measuring the relative numbers of replacement (R) mutations that lead to non-conservative amino acid changes (Rnc) to the combined numbers of conservative (Rc) and silent (S) amino acid R mutations that likely do not or cannot change amino acids, "(S+Rc) to Rnc IGHV mutation ratio". When comparing time-to-first-treatment (TTFT) of patients with (S+Rc)/Rnc ≤ 1 and >1, TTFTs were similar, even after matching groups for equal numbers of samples and identical numbers of mutations per sample. Thus, BCR structural change might not be the main reason for better outcomes for M-CLL. Since the total number of IGHV mutations associated better with longer TTFT, better clinical courses appear due to the biologic state of a B cell having undergone many stimulatory events leading to IGHV mutations. Analyses of larger patient cohorts will be needed to definitively answer this question.

Published
2022

5. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, and Kater, Arnon P.

Published
2022
Full Text
View/download PDF

7. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Author

Tedeschi, Alessandra, Frustaci, Anna Maria, Mauro, Francesca Romana, Chiarenza, Annalisa, Coscia, Marta, Ciolli, Stefania, Reda, Gianluigi, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Baratè, Claudia, Sportoletti, Paolo, Greco, Antonino, Borella, Chiara, Rossi, Valentina, Deodato, Marina, Biagi, Annalisa, Zamprogna, Giulia, Pelle, Angelo Curto, Lapietra, Gianfranco, Vitale, Candida, Morelli, Francesca, Cassin, Ramona, Fresa, Alberto, Cavalloni, Chiara, Postorino, Massimiliano, Ielo, Claudia, Cairoli, Roberto, Di Raimondo, Francesco, Montillo, Marco, and Del Poeta, Giovanni

Published
2021
Full Text
View/download PDF

8. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, Forconi, Francesco, Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, and Forconi, Francesco

Published
2024

9. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Author

Tedeschi, A, Frustaci, A, Condoluci, A, Coscia, M, Chiarle, R, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Catania, G, Deodato, M, Jones, R, Tabanelli, V, Griggio, V, Stüssi, G, Calleri, A, Pini, K, Cairoli, R, Zenz, T, Signori, A, Zucca, E, Rossi, D, Montillo, M, Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, Montillo, Marco, Tedeschi, A, Frustaci, A, Condoluci, A, Coscia, M, Chiarle, R, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Catania, G, Deodato, M, Jones, R, Tabanelli, V, Griggio, V, Stüssi, G, Calleri, A, Pini, K, Cairoli, R, Zenz, T, Signori, A, Zucca, E, Rossi, D, Montillo, M, Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, and Montillo, Marco

Published
2024

10. S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Author

Frustaci, Anna Maria, primary, Montillo, Marco, additional, Rossi, Davide, additional, Zinzani, Pier Luigi, additional, Motta, Marina, additional, Gaidano, Gianluca, additional, Quaresmini, Giulia, additional, Scarfò, Lydia, additional, Pietrasanta, Daniela, additional, Coscia, Marta, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Cairoli, Roberto, additional, Stüssi, Georg, additional, Zucca, Emanuele, additional, Pileri, Stefano, additional, Zenz, Thorsten, additional, and Tedeschi, Alessandra, additional

Published
2023
Full Text
View/download PDF

11. Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

12. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, primary, Kavakiotis, Ioannis, primary, Agathangelidis, Andreas, primary, Sutton, Lesley-Ann, primary, Minga, Eva, primary, Ntoufa, Stavroula, primary, Tausch, Eugen, primary, Yan, Xiao-Jie, primary, Shanafelt, Tait, primary, Plevova, Karla, primary, Boudjogra, Myriam, primary, Rossi, Davide, primary, Davis, Zadie, primary, Navarro, Alba, primary, Sandberg, Yorick, primary, Vojdeman, Fie Juhl, primary, Scarfo, Lydia, primary, Stavroyianni, Niki, primary, Sudarikov, Andrey, primary, Veronese, Silvio, primary, Tzenou, Tatiana, primary, Karan-Djurasevic, Teodora, primary, Catherwood, Mark, primary, Kienle, Dirk, primary, Chatzouli, Maria, primary, Facco, Monica, primary, Bahlo, Jasmin, primary, Pott, Christiane, primary, Pedersen, Lone Bredo, primary, Mansouri, Larry, primary, Smedby, Karin E., primary, Chu, Charles C., primary, Giudicelli, Véronique, primary, Lefranc, Marie-Paule, primary, Panagiotidis, Panagiotis, primary, Juliusson, Gunnar, primary, Anagnostopoulos, Achilles, primary, Vlahavas, Ioannis, primary, Antic, Darko, primary, Trentin, Livio, primary, Montillo, Marco, primary, Niemann, Carsten, primary, Döhner, Hartmut, primary, Langerak, Anton W., primary, Pospisilova, Sarka, primary, Hallek, Michael, primary, Campo, Elias, primary, Chiorazzi, Nicholas, primary, Maglaveras, Nikos, primary, Oscier, David, primary, Gaidano, Gianluca, primary, Jelinek, Diane F., primary, Stilgenbauer, Stephan, primary, Chouvarda, Ioanna, primary, Darzentas, Nikos, primary, Belessi, Chrysoula, primary, Davi, Frederic, primary, Hadzidimitriou, Anastasia, primary, Rosenquist, Richard, primary, Ghia, Paolo, primary, and Stamatopoulos, Kostas, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 2A from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

15. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Author

Xochelli, Aliki, primary, Baliakas, Panagiotis, primary, Kavakiotis, Ioannis, primary, Agathangelidis, Andreas, primary, Sutton, Lesley-Ann, primary, Minga, Eva, primary, Ntoufa, Stavroula, primary, Tausch, Eugen, primary, Yan, Xiao-Jie, primary, Shanafelt, Tait, primary, Plevova, Karla, primary, Boudjogra, Myriam, primary, Rossi, Davide, primary, Davis, Zadie, primary, Navarro, Alba, primary, Sandberg, Yorick, primary, Vojdeman, Fie Juhl, primary, Scarfo, Lydia, primary, Stavroyianni, Niki, primary, Sudarikov, Andrey, primary, Veronese, Silvio, primary, Tzenou, Tatiana, primary, Karan-Djurasevic, Teodora, primary, Catherwood, Mark, primary, Kienle, Dirk, primary, Chatzouli, Maria, primary, Facco, Monica, primary, Bahlo, Jasmin, primary, Pott, Christiane, primary, Pedersen, Lone Bredo, primary, Mansouri, Larry, primary, Smedby, Karin E., primary, Chu, Charles C., primary, Giudicelli, Véronique, primary, Lefranc, Marie-Paule, primary, Panagiotidis, Panagiotis, primary, Juliusson, Gunnar, primary, Anagnostopoulos, Achilles, primary, Vlahavas, Ioannis, primary, Antic, Darko, primary, Trentin, Livio, primary, Montillo, Marco, primary, Niemann, Carsten, primary, Döhner, Hartmut, primary, Langerak, Anton W., primary, Pospisilova, Sarka, primary, Hallek, Michael, primary, Campo, Elias, primary, Chiorazzi, Nicholas, primary, Maglaveras, Nikos, primary, Oscier, David, primary, Gaidano, Gianluca, primary, Jelinek, Diane F., primary, Stilgenbauer, Stephan, primary, Chouvarda, Ioanna, primary, Darzentas, Nikos, primary, Belessi, Chrysoula, primary, Davi, Frederic, primary, Hadzidimitriou, Anastasia, primary, Rosenquist, Richard, primary, Ghia, Paolo, primary, and Stamatopoulos, Kostas, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 3 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Author

Davids, Matthew S., primary, Kuss, Bryone J., primary, Hillmen, Peter, primary, Montillo, Marco, primary, Moreno, Carol, primary, Essell, James, primary, Lamanna, Nicole, primary, Nagy, Zsolt, primary, Tam, Constantine S., primary, Stilgenbauer, Stephan, primary, Ghia, Paolo, primary, Delgado, Julio, primary, Lustgarten, Stephanie, primary, Weaver, David T., primary, Youssoufian, Hagop, primary, and Jäger, Ulrich, primary

Published
2023
Full Text
View/download PDF

19. Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Author

Trojani, A, Beghini, A, Bossi, L, Stefanucci, M, Palumbo, C, Greco, A, Frustaci, A, Di Camillo, B, Montillo, M, Cairoli, R, Trojani, Alessandra, Beghini, Alessandro, Bossi, Luca Emanuele Emanuele, Stefanucci, Marta Rachele, Palumbo, Cassandra, Greco, Antonino, Frustaci, Annamaria, Di Camillo, Barbara, Montillo, Marco, Cairoli, Roberto, Trojani, A, Beghini, A, Bossi, L, Stefanucci, M, Palumbo, C, Greco, A, Frustaci, A, Di Camillo, B, Montillo, M, Cairoli, R, Trojani, Alessandra, Beghini, Alessandro, Bossi, Luca Emanuele Emanuele, Stefanucci, Marta Rachele, Palumbo, Cassandra, Greco, Antonino, Frustaci, Annamaria, Di Camillo, Barbara, Montillo, Marco, and Cairoli, Roberto

Published
2023

20. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome

Author

Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, Tedeschi, Alessandra, Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, and Tedeschi, Alessandra

Published
2023

21. Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

Author

Frustaci, A, Deodato, M, Zamprogna, G, Cairoli, R, Montillo, M, Tedeschi, A, Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Montillo, Marco, Tedeschi, Alessandra, Frustaci, A, Deodato, M, Zamprogna, G, Cairoli, R, Montillo, M, Tedeschi, A, Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Montillo, Marco, and Tedeschi, Alessandra

Abstract

Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially for high-risk patients, and include BTK inhibitor combinations with BCl2 inhibitors with or without anti-CD20 monoclonal antibodies. Finally, new mechanisms for BTK inhibition are under investigations in patients progressing with both covalent and non-covalent BTK and BCl2 inhibitors. Here we summarize and discuss results from main experiences on irreversible and reversable BTK inhibitors in CLL.

Published
2023

23. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Author

Kaufman, Matthew, primary, Yan, Xiao-Jie, additional, Li, Wentian, additional, Ghia, Emanuela M., additional, Langerak, Anton W., additional, Rassenti, Laura Z., additional, Belessi, Chrysoula, additional, Kay, Neil E., additional, Davi, Frederic, additional, Byrd, John C., additional, Pospisilova, Sarka, additional, Brown, Jennifer R., additional, Catherwood, Mark, additional, Davis, Zadie, additional, Oscier, David, additional, Montillo, Marco, additional, Trentin, Livio, additional, Rosenquist, Richard, additional, Ghia, Paolo, additional, Barrientos, Jacqueline C., additional, Kolitz, Jonathan E., additional, Allen, Steven L., additional, Rai, Kanti R., additional, Stamatopoulos, Kostas, additional, Kipps, Thomas J., additional, Neuberg, Donna, additional, and Chiorazzi, Nicholas, additional

Published
2022
Full Text
View/download PDF

24. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, Laurenti, Luca (ORCID:0000-0002-8327-1396), Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

NA

Published
2022

25. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, primary, Frustaci, Anna Maria, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Murru, Roberta, additional, Visentin, Andrea, additional, Reda, Gianluigi, additional, Mauro, Francesca Romana, additional, Quaresmini, Giulia, additional, Vanazzi, Anna, additional, Vitale, Candida, additional, Orsucci, Lorella, additional, Massaia, Massimo, additional, Sanna, Alessandro, additional, Motta, Marina, additional, Ibatici, Adalberto, additional, Ferrarini, Isacco, additional, Borella, Chiara, additional, Varettoni, Marzia, additional, Tani, Monica, additional, Marinoni, Sara, additional, Ferrario, Andrea, additional, Zamprogna, Giulia, additional, Montillo, Marco, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

26. sj-docx-1-tah-10.1177_20406207221127550 – Supplemental material for Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Author

Frustaci, Anna Maria, Del Poeta, Giovanni, Visentin, Andrea, Sportoletti, Paolo, Fresa, Alberto, Vitale, Candida, Murru, Roberta, Chiarenza, Annalisa, Sanna, Alessandro, Mauro, Francesca Romana, Reda, Gianluigi, Gentile, Massimo, Varettoni, Marzia, Baratè, Claudia, Borella, Chiara, Greco, Antonino, Deodato, Marina, Zamprogna, Giulia, Laureana, Roberta, Cipiciani, Alessandra, Galitzia, Andrea, Curto Pelle, Angelo, Morelli, Francesca, Malvisi, Lucio, Coscia, Marta, Laurenti, Luca, Trentin, Livio, Montillo, Marco, Cairoli, Roberto, and Tedeschi, Alessandra

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tah-10.1177_20406207221127550 for Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia by Anna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, Paolo Sportoletti, Alberto Fresa, Candida Vitale, Roberta Murru, Annalisa Chiarenza, Alessandro Sanna, Francesca Romana Mauro, Gianluigi Reda, Massimo Gentile, Marzia Varettoni, Claudia Baratè, Chiara Borella, Antonino Greco, Marina Deodato, Giulia Zamprogna, Roberta Laureana, Alessandra Cipiciani, Andrea Galitzia, Angelo Curto Pelle, Francesca Morelli, Lucio Malvisi, Marta Coscia, Luca Laurenti, Livio Trentin, Marco Montillo, Roberto Cairoli and Alessandra Tedeschi in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

27. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Author

Frustaci, Anna Maria, primary, Del Poeta, Giovanni, additional, Visentin, Andrea, additional, Sportoletti, Paolo, additional, Fresa, Alberto, additional, Vitale, Candida, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Sanna, Alessandro, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Gentile, Massimo, additional, Varettoni, Marzia, additional, Baratè, Claudia, additional, Borella, Chiara, additional, Greco, Antonino, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Laureana, Roberta, additional, Cipiciani, Alessandra, additional, Galitzia, Andrea, additional, Curto Pelle, Angelo, additional, Morelli, Francesca, additional, Malvisi, Lucio, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Trentin, Livio, additional, Montillo, Marco, additional, Cairoli, Roberto, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

29. Genetic Landscape and Clonal Evolution Patterns of CEBPA-Mutated Acute Myeloid Leukaemia Based on Next-Generation Sequencing: A Retrospective Analysis

Author

Leuzzi, Livia, primary, Mancini, Valentina, additional, Veronese, Silvio Marco, additional, Pezzetti, Laura, additional, Motta, Valentina, additional, Nichelatti, Michele, additional, Greco, Rosa, additional, Bertani, Giambattista, additional, Montillo, Marco, additional, Beghini, Alessandro, additional, and Cairoli, Roberto, additional

Published
2021
Full Text
View/download PDF

30. Common Gene Expression Signature of B-Cells of Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance (IgM MGUS) Compared to Healthy Subjects

Author

Trojani, Alessandra, primary, Di Camillo, Barbara, additional, Bossi, Luca Emanuele, additional, Greco, Antonino, additional, Leuzzi, Livia, additional, Tedeschi, Alessandra, additional, Frustaci, Anna Maria, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Melluso, Agostina, additional, Panzeri, Alessia, additional, Montillo, Marco, additional, Beghini, Alessandro, additional, and Cairoli, Roberto, additional

Published
2021
Full Text
View/download PDF

32. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.

Author

Staber, Philipp Bernhard, Jurczak, Wojciech, Greil, Richard, Vucinic, Vladan, Middeke, Jan Moritz, Montillo, Marco, Munir, Talha, Neumeister, Peter, Schetelig, Johannes, Stilgenbauer, Stephan, Striebel, Frank, Dirnberger-Hertweck, Maren, Weirather, Johannes, Brugger, Wolfram, Kelemen, Peter, Wendtner, Clemens-Martin, and Woyach, Jennifer Ann

Subjects
BRUTON tyrosine kinase, FLUDARABINE, VENETOCLAX, PROTEIN-tyrosine kinase inhibitors, CHRONIC lymphocytic leukemia
Abstract

Patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) whose treatment failed with a Bruton's tyrosine kinase inhibitor have poor outcomes. We investigated tafasitamab plus idelalisib (cohort A) or venetoclax (cohort B) in this patient population in a phase II study (NCT02639910). In total, 24 patients were enrolled (cohort A: n = 11, median time on study, 7.4 months; cohort B: n = 13, median time on study, 15.6 months). The most common treatment-emergent adverse event (TEAE) in cohort A was anemia (63.6%) and in cohort B was infusion-related reaction (53.8%). The most common severe TEAE was neutropenia (cohort A: 45.5%; cohort B: 46.2%). The best overall response rate was 90.9% (cohort A) and 76.9% (cohort B). Undetectable minimal residual disease in peripheral blood was achieved in 2/8 patients (cohort A) and 6/7 patients (cohort B). Overall, these results suggest that anti-CD19 antibody-based combinations may be important in the treatment of patients with CLL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.

Author

Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stüssi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, and Tedeschi, Alessandra

Published
2023
Full Text
View/download PDF

35. Common Gene Expression Signature of B-Cells of WaldenströmMacroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance (IgM MGUS) Compared to Healthy Subjects

Author

Trojani, Alessandra, Di Camillo, Barbara, Bossi, Luca Emanuele, Greco, Antonino, Leuzzi, Livia, Tedeschi, Alessandra, Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Melluso, Agostina, Panzeri, Alessia, Montillo, Marco, Beghini, Alessandro, and Cairoli, Roberto

Abstract

We performed a comparative gene expression profiling (GEP) study on B-cells and plasma cells of WaldenströmMacroglobulinemia (WM), IgM monoclonal gammopathies of undetermined significance (IgMMGUS), and normal individuals (CTRLs) to identify GEP changes as reliable predictors of progression of IgMMGUS to WM.

Published
2021
Full Text
View/download PDF

36. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.

Author

Deodato, Marina, Frustaci, Anna Maria, Zappaterra, Arianna, Rapella, Alberto, Gambacorti-Passerini, Carlo, Cairoli, Roberto, Montillo, Marco, and Tedeschi, Alessandra

Subjects
*DIFFUSE large B-cell lymphomas, *RICHTER syndrome, *CHRONIC lymphocytic leukemia, *BISPECIFIC antibodies, *MOLECULAR genetics
Abstract

AbstractRichter’s transformation (RT) is defined as the evolution of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. This complication is rare and aggressive, with poor prognosis and dismal survival. Clonal relationship with the underlying CLL/SLL, observed in ∼80% of cases, represents one of the main factors affecting prognosis. Treatment has been historically based on chemoimmunotherapy, but frequent mutations in genes involved in cell survival and proliferation—such as TP53, NOTCH1, MYC, CDKN2A—confer resistance to standard treatments. During the last years, advances in the knowledge of the biological mechanisms underlying RT allowed to identify genetic and molecular lesions that can potentially be targeted by novel selective agents. Pathway and checkpoint inhibitors, bispecific antibodies and CAR T-cell therapy are currently under investigation and represent promising treatment options. This review summarizes current biological evidence and available data on novel therapeutic agents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results